DRI Healthcare Trust (TSE:DHT.UN) Shares Down 0.5% - Here's Why

Key Points

• DRI Healthcare Trust's share price decreased by 0.5%, trading between C$14.50 and C$14.56 during the day, with a significant drop in trading volume.
• The company declared a quarterly dividend of $0.10, which represents a 2.7% yield and a high dividend payout ratio of 528.57%.
• DRI Healthcare Trust has a market capitalization of C$808.09 million and operates in the pharmaceutical and biotechnology markets, focusing on managing a diversified portfolio of pharmaceutical royalties.

DRI Healthcare Trust (TSE:DHT.UN - )'s share price dropped 0.5% during mid-day trading on Wednesday . The stock traded as low as C$14.50 and last traded at C$14.56. Approximately 24,437 shares traded hands during trading, a decline of 43% from the average daily volume of 43,207 shares. The stock had previously closed at C$14.64.

DRI Healthcare Trust Price Performance

The firm has a market cap of C$808.09 million, a P/E ratio of 208.00 and a beta of 0.13. The company has a fifty day moving average of C$14.51 and a 200-day moving average of C$13.27.

DRI Healthcare Trust Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 20th. Shareholders of record on Monday, October 20th will be paid a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Monday, September 29th. DRI Healthcare Trust's dividend payout ratio is 528.57%.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.